Exciting news from Health Canada! They’ve broadened the approval of Jemperli (dostarlimab) in combination with chemotherapy for all adults facing primary advanced or first recurrent endometrial cancer. This groundbreaking treatment is the first in immuno-oncology to show a remarkable overall survival benefit.